J&J’s Multiple Myeloma Therapies Impress with New Data at EHA26

J&J Presents Strong Data for Talvey and Tecvayli in Multiple Myeloma

Johnson & Johnson presented new data for its approved multiple myeloma (MM) therapies, Talvey (talquetamab) and Tecvayli (teclistamab-cqyv), at the European Hematology Association (EHA) conference. The Phase III MonumenTAL-3 trial for Talvey in relapsed or refractory MM (R/R MM) demonstrated a profound progression-free survival (PFS) benefit for Talvey plus Darzalex and pomalidomide (Tal-DP) and Talvey plus daratumumab (Tal-D) regimens, with hazard ratios of 0.28 and 0.33 respectively, both p<0.0001, compared to DPd. This translated to significantly higher 24-month PFS rates and objective response rates. J&J plans US and EU filings for Talvey later in 2026, aiming for a new standard of care as early as 2L. Additionally, data from the Phase III MajesTEC-3 trial for Tecvayli showed unprecedented PFS improvement, and the Phase II ImmunoPRISM trial supported Tecvayli as an intervention for high-risk smoldering MM.

• The Phase III MonumenTAL-3 trial (NCT05455320) showed Talvey-based regimens (Tal-DP and Tal-D) significantly improved progression-free survival (PFS) in relapsed or refractory multiple myeloma patients. At 24.6 months median follow-up, HRs versus DPd were 0.28 for Tal-DP and 0.33 for Tal-D (both p<0.0001). This led to 24-month PFS rates of 81.3% for Tal-DP and 77.6% for Tal-D, compared to 51.2% for DPd, alongside superior objective response rates and complete response rates.
• Talvey regimens demonstrated manageable safety profiles consistent with known agents. The Tal-D doublet offers a distinct safety profile with comparable efficacy, potentially benefiting patients with specific comorbidities. J&J plans US and EU filings for Talvey later in 2026, aiming to establish it as a new standard of care as early as the second line, positioning it alongside J&J's own Tecvayli in this treatment space.
• Data from the Phase III MajesTEC-3 trial (NCT05083169) for Tecvayli plus daratumumab (Tec-Dara) showed an unprecedented PFS improvement (36-month HR of 0.17) in R/R MM patients with one to three prior lines of therapy. This supports Tecvayli's potential approval as a standard of care as early as the second line, advancing from its prior accelerated FDA approval in the fourth line. The data also highlighted Tec-Dara's consistent efficacy across high-risk subgroups.
• The Phase II ImmunoPRISM trial (NCT05469893) investigated Tecvayli monotherapy in high-risk smoldering multiple myeloma (SMM). Tecvayli-treated patients achieved a 73% complete response rate and 81% MRD negativity, significantly outperforming the lenalidomide plus dexamethasone (LenDex) group (0% for both). The two-year PFS rate was 92% for Tecvayli versus 51% for LenDex, suggesting Tecvayli could be a suitable intervention for this pre-malignant stage.

MonumenTAL-3: Talvey's Profound Benefit in Relapsed/Refractory MM

Recent clinical investigation in multiple myeloma spans a broad range of treatment modalities — from CD38-directed monoclonal antibodies and CAR-T therapies to bispecific antibodies and novel combination regimens — across both newly diagnosed and relapsed/refractory settings. The studies below reflect a cross-section of pivotal and real-world evidence published in recent years, highlighting both efficacy benchmarks and emerging safety considerations.

MajesTEC-3: Tecvayli's Differentiation in High-Risk R/R MM

The comparative efficacy of investigational and standard-of-care (SOC) therapies in multiple myeloma is well-documented across large randomized trials and meta-analyses. A meta-analysis of 11 randomized controlled trials encompassing 5,270 patients demonstrated that anti-CD38 monoclonal antibody-based regimens significantly outperformed standard therapy in newly diagnosed MM, improving MRD negativity rates (RR 1.94, 95% CI: 1.59–2.37; p < 0.00001) and progression-free survival (RR 0.51, 95% CI: 0.45–0.58; p < 0.00001). The benefit was observed in both transplant-eligible and transplant-ineligible populations, with particularly pronounced MRD negativity gains in the latter group (RR 3.49, 95% CI: 2.65–4.61). In the IKEMA trial, isatuximab combined with carfilzomib-dexamethasone (Isa-Kd) achieved a median PFS of 35.7 months versus 19.2 months with Kd alone (HR 0.58, 95.4% CI: 0.42–0.79), alongside stringent CR/CR rates of 44.1% versus 28.5% and MRD negativity rates of 33.5% versus 15.4%. The ALCYONE trial's final analysis further reinforced the SOC value of daratumumab-based regimens, with D-VMP delivering a median OS of 83.0 months compared to 53.6 months with VMP alone (HR 0.65, 95% CI: 0.53–0.80; p < 0.0001) in transplant-ineligible newly diagnosed patients.

In the relapsed/refractory setting, emerging bispecific antibodies and next-generation agents continue to demonstrate differentiated profiles against established regimens. Elranatamab, a BCMA-directed bispecific antibody, has shown encouraging efficacy with a manageable safety profile in R/R MM, with a low incidence of high-grade cytokine release syndrome supporting potential outpatient administration, though high infection rates remain a clinical challenge. Network meta-analyses of approved R/R MM regimens have highlighted meaningful differences in the efficacy-safety balance: carfilzomib plus dexamethasone ranked most favorably on a composite efficacy-safety endpoint (SUCRA 0.61), while the panobinostat-bortezomib-dexamethasone combination ranked lowest (SUCRA 0.24). Real-world sequencing data from 121 patients comparing carfilzomib-then-pomalidomide versus pomalidomide-then-carfilzomib showed comparable outcomes regardless of order, with median PFS of 4.93 and 5.36 months, and median OS of 11.01 and 10.98 months, respectively, suggesting treatment flexibility in later lines.

Across the broader investigational landscape, phase I trial data from 74 studies (n = 2,408 MM patients, 2004–2015) offers a calibrating perspective on early-phase signal detection: the median ORR for single-agent investigational therapies was 13.2%, rising to 19% in trials that advanced to phase II and 23% for agents that ultimately achieved FDA approval, versus 8% for those that did not (HR 2.21, 95% CI: 2.01–2.61; p = 0.012). Importantly, real-world applicability remains a persistent consideration, as approximately 40% of MM patients in clinical practice do not meet eligibility criteria for the phase III trials underpinning regulatory approvals. Treatment decisions must therefore account for patient-specific factors including cytogenetic risk, comorbidities, treatment burden, and quality of life — dimensions not always fully captured in trial-level comparative data.

ImmunoPRISM: Tecvayli's Potential in High-Risk Smoldering MM

Despite meaningful advances in multiple myeloma (MM) therapeutics, the disease remains incurable, and several patient populations continue to face disproportionately poor outcomes. High-risk disease — defined by adverse cytogenetic abnormalities, extramedullary involvement, or plasma cell leukemia — represents one of the most critical unmet needs, with patients in these subgroups demonstrating markedly inferior progression-free and overall survival regardless of treatment line. Heavily pretreated patients, including those who are double- or triple-class refractory, also remain underserved: real-world data show that lenalidomide-refractory patients receiving second-line daratumumab-bortezomib-dexamethasone achieve a median time to next treatment or death of approximately 10 months, underscoring the inadequacy of current sequencing strategies. Beyond refractory disease, the role of minimal residual disease (MRD) as a treatment decision tool, the impact of relapse type (biochemical versus clinical) on maintenance selection, and the optimal choice of first-relapse therapy following maintenance all represent clinically significant gaps yet to be resolved.

Frailty and advanced age constitute a second major area of unmet need. More than half of MM patients are ineligible for autologous stem cell transplantation, and this heterogeneous population — spanning frail, elderly, and comorbid individuals — lacks standardized treatment approaches. Geriatric assessment has been identified as a more reliable guide to treatment selection than chronological age or comorbidity indices alone, yet GA-informed clinical trial designs remain limited. Very elderly patients (>80 years) represent a particularly underrepresented cohort in pivotal trials, leaving clinicians without robust evidence to guide dosing modulation or regimen selection. Quantifying frailty to adapt treatment schedules has shown potential to reduce toxicity-related morbidity and mortality, but validated tools and prospective data in this population remain scarce.

Racial, geographic, and socioeconomic disparities further compound the unmet need landscape. Black patients in the United States are diagnosed with MM at twice the rate of White patients, yet are significantly less likely to receive advanced cellular therapies such as CAR-T, with odds ratios as low as 0.33 in some analyses. In resource-constrained settings — including the Middle East, Latin America, and lower-income regions of Asia — access to novel immunotherapies is severely limited, and low diagnostic capacity leads to systematic underestimation of disease burden. Asia now accounts for 35.8% of global MM incident cases and 39.7% of global DALYs as of 2021, with growth rates exceeding the global average, yet healthcare infrastructure in many Asian subregions cannot support equitable access to emerging treatment modalities. Addressing these disparities will require realistic, regionally adapted clinical guidelines that explicitly account for drug accessibility, cost, and local expertise.

J&J's Bispecifics Poised to Redefine Multiple Myeloma Care

The latest clinical updates from EHA underscore a significant strengthening of the bispecific antibody landscape in multiple myeloma, particularly for Johnson & Johnson's portfolio. The MonumenTAL-3 trial results for talquetamab are particularly impactful, demonstrating a profound progression-free survival benefit when combined with daratumumab and pomalidomide (Tal-DP) or daratumumab alone (Tal-D) in relapsed or refractory multiple myeloma (R/R MM). This robust efficacy, with hazard ratios as low as 0.28, positions talquetamab as a strong contender for a new standard of care as early as the second line of therapy, moving beyond its current use in heavily pretreated patients. This potential shift could significantly expand its market reach and redefine treatment sequencing.

Simultaneously, teclistamab continues to demonstrate its clinical value. The MajesTEC-3 trial reinforces its unprecedented PFS improvement in R/R MM, while the ImmunoPRISM trial explores its utility in high-risk smoldering MM. This latter development is a strategic move towards earlier intervention, potentially delaying disease progression and offering a novel therapeutic avenue for patients before active myeloma develops.

However, the widespread adoption of these powerful T-cell redirecting therapies comes with important considerations. Both teclistamab and talquetamab are associated with immune-related toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which, while generally manageable, require vigilant monitoring. Infections, including severe ones, are also a notable risk, with real-world data highlighting the importance of prophylactic measures like IVIG. Furthermore, the literature suggests that patient immune fitness, including baseline T-cell counts and the presence of immunosuppressive regulatory T cells, can influence response and contribute to acquired resistance, underscoring the need for ongoing research into optimal sequencing and combination strategies to overcome these challenges and maximize long-term patient benefit.